Johnson & Johnson Innovative Medicine — Percent Change (as a percent) decreased by 11.2% to $0.21 in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 13.9%, from $0.19 to $0.21. This decline may warrant attention — for this metric, higher values are generally preferred.
Positive growth indicates expanding market share or successful product launches; negative growth suggests market saturation or competitive pressure.
Calculates the period-over-period growth rate of the Innovative Medicine segment's sales. This metric normalizes perform...
Standard 'Revenue Growth Rate' reported by all public companies for their business segments.
jnj_segment_innovative_medicine_percent_change_as_a_percent| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.02 | $0.02 | $0.02 | $0.02 | -$0.34 | -$0.48 | $0.16 | $0.19 | -$0.09 | $0.22 | $0.24 | $0.21 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | <-999% | -43.7% | +132.5% | +19.1% | -149.2% | +342.4% | +7.6% | -11.2% |
| YoY Change | — | — | — | — | <-999% | — | — | +155.7% | — | +146.2% | +52.9% | +13.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.